← Back
Data updated: Mar 10, 2026
Bristol-Myers Squibb
BMY OncologyImmunologyGastroenterology
Oncology and immunology leader with Opdivo, Revlimid, and Eliquis franchises. Known for strategic acquisitions including Celgene and recent cell therapy deals.
$48.3B
Revenue (2024)
$95.0B
Market Cap
-
Trials
75
Approved (2yr)
Key Drugs
Recent Activity
NARCAN 2026-02-11
Labeling
NARCAN 2026-01-09
Labeling
OTEZLA 2025-12-23
Labeling
OPDIVO QVANTIG 2025-11-24
Efficacy
NARCAN 2025-11-21
Labeling
OPDIVO QVANTIG 2025-10-27
Efficacy
OPDIVO QVANTIG 2025-10-27
Efficacy
OTEZLA 2025-08-29
Type 5 - New Formulation or New Manufacturer
OTEZLA 2025-08-29
Type 5 - New Formulation or New Manufacturer
CLINDAMYCIN PHOSPHATE 2025-08-22
Labeling
SEC Filings
Pro
Loading...
Therapeutic Focus
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Oncology 66%
12 drugs Phase 3: 76 Phase 2: 81 Phase 1: 161
Immunology 18%
1 drugs Phase 3: 27 Phase 2: 21 Phase 1: 39
Gastroenterology 6%
1 drugs Phase 3: 5 Phase 2: 11 Phase 1: 19
Infectious Disease 5%
4 drugs Phase 3: 3 Phase 2: 8 Phase 1: 4
Neurology 5%
0 drugs Phase 3: 10 Phase 2: 3 Phase 1: 4
Pipeline Strength Pro
Loading...
Competitors Pro
Pfizer big-pharma
Oncology, Infectious Disease, Immunology, Gastroenterology
AbbVie big-pharma
Immunology, Oncology, Neurology, Infectious Disease
GSK big-pharma
Infectious Disease, Oncology, Immunology, Neurology
Takeda big-pharma
Immunology, Oncology, Gastroenterology, Neurology
Merck big-pharma
Oncology, Infectious Disease, Immunology
Active (36)
ELIQUIS SPRINKLE OPDIVO QVANTIG COBENFY AUGTYRO KRAZATI SOTYKTU CAMZYOS OPDUALAG ONUREG ZEPOSIA REBLOZYL INREBIC IDHIFA EMPLICITI EVOTAZ OPDIVO OTEZLA POMALYST ELIQUIS NULOJIX YERVOY ISTODAX SPRYCEL REVLIMID ORENCIA BARACLUDE ABRAXANE VIDAZA REYATAZ THALOMID ETOPOPHOS PRESERVATIVE FREE CLINDAMYCIN PHOSPHATE AZACTAM HALOG NARCAN NEOMYCIN SULFATE
Discontinued (70)
NYDRAZID ESTRACE SUSTIVA PRAVACHOL NUPRIN PENICILLIN G SODIUM DAKLINZA MEGACE GLUCOVANCE VIDEX ZERIT VIDEX EC AZACTAM IN PLASTIC CONTAINER COUMADIN METAGLIP BUSPAR BLENOXANE SERZONE STADOL PROLIXIN DECANOATE MONOPRIL MONOPRIL-HCT RUBRAMIN PC GLUCOSCAN ZERIT XR PRAVIGARD PAC (COPACKAGED) TESLAC FUNGIZONE PRINCIPEN TUBOCURARINE CHLORIDE RUBEX VITAMIN A MUTAMYCIN QUESTRAN LIGHT QUESTRAN VELOSEF VINCREX MEXATE-AQ PRESERVED MEXATE MEXATE-AQ PRECEF AMITID OXYCODONE 2.5/APAP 500 OXYCODONE 5/APAP 500 POLYCILLIN-PRB TETREX BRISTACYCLINE BRISTAMYCIN STILBESTROL VERSAPEN-K
+20 more
Company Info
- First Approval
- 1945-02-20
- Latest
- 2025-11-24
- Applications
- 134
FDA Sponsor Names
BRISTOL MYERS SQUIBBBRISTOLBRISTOL-MYERS SQUIBBCELGENEBRISTOL-MYERS +3